Mechanism of Hydralazine-Induced Fluid Retention
Hydralazine causes fluid retention through activation of the renin-angiotensin-aldosterone system (RAAS) in response to decreased renal perfusion pressure from arterial vasodilation, leading to increased aldosterone secretion and consequent sodium and water reabsorption. 1
Primary Mechanism: RAAS Activation
Hydralazine preferentially dilates arterioles while having minimal effect on venous tone, which reduces arterial blood pressure and decreases renal perfusion pressure 1, 2
The reduction in renal perfusion pressure triggers increased renin secretion by the juxtaglomerular cells as a compensatory reflex response to the perceived decrease in effective circulating volume 1
Elevated renin activity leads to angiotensin II production, which stimulates aldosterone release from the adrenal cortex, resulting in enhanced sodium reabsorption in the distal tubules and collecting ducts 1
This aldosterone-mediated sodium retention is accompanied by water retention, manifesting clinically as fluid accumulation and weight gain 3, 4
Compensatory Hemodynamic Responses
Baroreflex-mediated venoconstriction occurs in response to arterial vasodilation, increasing venous return to the heart and contributing to volume expansion 3
The reflex sympathetic activation that accompanies hydralazine use further promotes renal sodium retention through direct renal sympathetic nerve stimulation 3
Clinical Implications and Management
The American College of Cardiology recommends using hydralazine with concurrent diuretic therapy specifically to counteract this predictable sodium and fluid retention 5
Beta-blockers should also be co-administered to blunt the reflex sympathetic activation that contributes to both tachycardia and sodium retention 5, 3
Weight gain of approximately 1 kg or more is commonly observed during hydralazine therapy and serves as a clinical marker of fluid accumulation 4
Why Hydralazine Differs from Balanced Vasodilators
Unlike nitroprusside or nitrates that dilate both arteries and veins, hydralazine's selective arterial vasodilation without venodilation fails to reduce cardiac preload, leaving the heart exposed to increased venous return 6
This hemodynamic profile explains why hydralazine monotherapy is inadequate and must be combined with diuretics to prevent symptomatic fluid overload in both hypertension and heart failure management 7, 3